bg-logo-sd
bg-icon-sd
April 2025

Lilly weight-loss pill works as well as Ozempic, shares surge

Eli Lilly’s experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to seek regulatory approvals by the end of the year.

Kevin T. Gade
Chief Operating Officer Principal & Portfolio Manager
kgade@bahl-gaynor.com

Continue reading more HERE to hear insights from Bahl & Gaynor’s very own, Kevin Gade.

Contact Us

© Copyright 2025 | Bahl & Gaynor, 255 East Fifth Street, Suite 2700 Cincinnati, OH 45202
Linkedin-in X-twitter

You're Leaving

You are now leaving the Bahl & Gaynor main website and entering into the Active ETFs website. By continuing to this link, we are not making any representation, warranty, or endorsement about the website and we are not providing you with investment advice or offering securities for sale to you.

Cancel
Continue